GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com
Patient Information Leaflet last updated on the eMC: 19/06/2009
PIL Zantac Effervescent Tablets 150mg and 300mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 19/06/2009 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
  • Change due to user-testing of patient information
Updated on 23/08/2006 and displayed until 19/06/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 14/11/2005 and displayed until 23/08/2006
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 22/06/2004 and displayed until 14/11/2005
Reasons for adding or updating:
  • Change to storage instructions
  • Change to date of revision
  • Change to side-effects
Updated on 23/08/2002 and displayed until 22/06/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 06/12/2000 and displayed until 23/08/2002
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   ranitidine hydrochloride


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk